On October 29, 2015 Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, reported the acceptance of four abstracts for poster presentations at the 27th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts (Press release, Ignyta, OCT 29, 2015, View Source [SID:1234507838]). The presentations relate to the company’s three clinical-stage product candidates, entrectinib, RXDX-105 and RXDX-107, and will be made on November 6-8, 2015.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to sharing data for each of these development programs in this prestigious forum, and to discussing the data and our future plans with key scientific and clinical experts."
"We are honored that the Scientific Program Committee has selected our four abstracts for poster presentations, consisting of a clinical presentation relating to our RXDX-105 product candidate for which we will be presenting recent safety, PK and efficacy data, and preclinical presentations relating to each of our product candidates entrectinib, RXDX-105 and RXDX-107," said Pratik Multani, M.D., Chief Medical Officer of Ignyta. "We look forward to sharing data for each of these development programs in this prestigious forum, and to discussing the data and our future plans with key scientific and clinical experts."
Details of the presentations are as follows:
Date/time: Friday, November 6, 2015, 12:15 PM – 3:15 PM, Eastern Time
Title: Potent anti-tumor activity of entrectinib in patient-derived models harboring oncogenic gene rearrangements of NTRKs. (Poster number A173)
Date/time: Friday, November 6, 2015, 12:15 PM – 3:15 PM, Eastern Time
Title: RXDX-105 demonstrates potent RET inhibitory activity with therapeutic potential in multiple preclinical models of RET-rearrangement driven cancer. (Poster number A174)
Date/time: Saturday, November 7, 2015, 12:30 PM – 3:30 PM, Eastern Time
Title: RXDX-107, a dodecanol alkyl ester of bendamustine, demonstrates improved pharmacokinetic properties and significant anti-tumor efficacy in preclinical models of solid tumors. (Poster number B177)
Date/time: Sunday, November 8, 2015, 12:30 PM – 3:30 PM, Eastern Time
Title: A phase 1 study of RXDX-105, an oral RET, BRAF and EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic cancers. (Poster number C188)